THIS IS HUGE!!!, page-47

If it's true that it was the Top 20 steamrolling the traders in the last couple of weeks, then the data room is open imo.

The good Dr C. has been transparent in the recent newsletter:

“There is significant international interest in ADCs at present, and Patrys believes that the unique attributes of deoxymabs make them attractive to explore as potential new ADC therapeutics. Patrys also believes that a potential clinic-ready asset complemented by substantial pre-clinical data on platform applications will make a more compelling partnering opportunity."

Then re patents... Dr Greenwood adds:

"Like many other small biotechnology companies, Patrys’ potential exit strategies include out-licensing or selling its technology to another party. To be successful in this, we must ensure the patent portfolio remains robust with built-in flexibility. It is particularly important to consider what a potential future sub-licensee’s and/or acquirer’s patent needs are and to maximise the benefits from the portfolio."